Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges

[1]  E. Giovannetti,et al.  Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges , 2019, Cellular Oncology.

[2]  P. A. Futreal,et al.  Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer , 2018, Nature Communications.

[3]  C. Rudin,et al.  Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study , 2018, Pneumologie.

[4]  G. Wildey,et al.  Frequency of NOTCH pathway mutation in primary tumor of SCLC compared to metastatic biopsies and association with better survival. , 2018 .

[5]  Paolo A Ascierto,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[6]  J. Minna,et al.  Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. , 2018, Translational lung cancer research.

[7]  T. Kohno,et al.  Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. , 2017, Molecular and clinical oncology.

[8]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[9]  J. Soria,et al.  First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Chen,et al.  HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II. , 2018, American journal of translational research.

[11]  Y. Nakanishi,et al.  Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. , 2018, Lung cancer.

[12]  M. Odenthal,et al.  Notch signaling triggers the tumor heterogeneity of small cell lung cancer. , 2017, Journal of thoracic disease.

[13]  K. Rabe,et al.  Advanced Non-Small-Cell Lung Cancer. , 2017, New England Journal of Medicine.

[14]  Jing He,et al.  JCES 01.17 The Correlation of DLL3 Expression with High-Grade Pulmonary Neuroendocrine Carcinoma Clinicopathologic Features and Prognose , 2017 .

[15]  M. Brzozowa-Zasada,et al.  Notch and its oncogenic activity in human malignancies , 2017, European Surgery.

[16]  A. Oronsky,et al.  What's New in SCLC? A Review , 2017, Neoplasia.

[17]  H. Beltran,et al.  436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors , 2017 .

[18]  Jing Wang,et al.  Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies , 2017, Oncotarget.

[19]  K. Rabe,et al.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.

[20]  C. Rudin,et al.  Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. , 2017, Cancer research.

[21]  P. Komarnitsky,et al.  A phase III study of rovalpituzumab tesirine maintenance therapy following first-line platinum-based chemotherapy in patients with extensive disease small cell lung cancer (ED SCLC). , 2017 .

[22]  C. Rudin,et al.  Unravelling the biology of SCLC: implications for therapy , 2017, Nature Reviews Clinical Oncology.

[23]  Y. Ishikawa,et al.  Correlation between histone acetylation and expression of Notch1 in human lung carcinoma and its possible role in combined small-cell lung carcinoma. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[24]  K. Garcia,et al.  Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer , 2017, Nature.

[25]  J. Aster,et al.  The Varied Roles of Notch in Cancer. , 2017, Annual review of pathology.

[26]  M. Nishimura,et al.  Expression of Notch1 and Numb in small cell lung cancer , 2017, Oncotarget.

[27]  M. Brzozowa-Zasada,et al.  Notch signalling pathway as an oncogenic factor involved in cancer development , 2016, Contemporary oncology.

[28]  D. Generali,et al.  No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials. , 2016, Clinical lung cancer.

[29]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[30]  J. Crabtree,et al.  Notch Signaling in Neuroendocrine Tumors , 2016, Front. Oncol..

[31]  A. Nicholson,et al.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  Takaaki Ito,et al.  Evaluation of role of Notch3 signaling pathway in human lung cancer cells , 2016, Journal of Cancer Research and Clinical Oncology.

[33]  T. Buhl,et al.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas , 2015, International journal of cancer.

[34]  Takaaki Ito,et al.  Notch1 controls cell chemoresistance in small cell lung carcinoma cells , 2015, Thoracic cancer.

[35]  Mustafa Saad,et al.  Implications for Therapy , 2016 .

[36]  C. Rudin,et al.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.

[37]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[38]  Takaaki Ito,et al.  Notch1 controls cell invasion and metastasis in small cell lung carcinoma cell lines. , 2014, Lung cancer.

[39]  Takaaki Ito,et al.  Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma. , 2014, Lung cancer.

[40]  Y. Summers,et al.  Third-line chemotherapy in small-cell lung cancer: an international analysis. , 2014, Clinical lung cancer.

[41]  S. Akiyama,et al.  Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity , 2012, Molecular Cancer Therapeutics.

[42]  Kwok-Kin Wong,et al.  Characterization of the cell of origin for small cell lung cancer , 2011, Cell cycle.

[43]  E. Kremmer,et al.  Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. , 2011, Human molecular genetics.

[44]  V. Torri,et al.  Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. , 2010, Lung cancer.

[45]  M. Brock,et al.  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. , 2009, Cancer research.

[46]  Shuta Tomida,et al.  Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. , 2008, Cancer research.

[47]  E. Kremmer,et al.  Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo , 2007, The Journal of cell biology.

[48]  Herb Chen,et al.  Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. , 2007, The oncologist.

[49]  J. Boulter,et al.  The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands , 2005, The Journal of cell biology.

[50]  A. Berns,et al.  Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[51]  S. Baylin,et al.  Notch signaling induces cell cycle arrest in small cell lung cancer cells. , 2001, Cancer research.

[52]  R. J. Fleming,et al.  Structural conservation of Notch receptors and ligands. , 1998, Seminars in cell & developmental biology.

[53]  S. Baylin,et al.  An achaete-scute homologue essential for neuroendocrine differentiation in the lung , 1997, Nature.

[54]  R. Kageyama,et al.  Targeted disruption of mammalian hairy and Enhancer of split homolog-1 (HES-1) leads to up-regulation of neural helix-loop-helix factors, premature neurogenesis, and severe neural tube defects. , 1995, Genes & development.